Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cara taps Korean firm as first licensee for its lead analgesic

This article was originally published in Scrip

Executive Summary

The US venture Cara Therapeutics has struck the first licensing deal for its lead product candidate CR845, allying with Chong Kun Dang Pharmaceutical (CKD) for the development and marketing of the analgesic in South Korea.

You may also be interested in...



Cara Ready To Move Into Pivotal Studies In ESRD Pruritus

With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

Topics

Related Companies

UsernamePublicRestriction

Register

SC017259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel